80 results
Page 2 of 4
8-K
EX-99.1
9os41g
10 May 21
FibroGen Reports First Quarter 2021 Financial Results
4:07pm
8-K
EX-99.1
txchl7p
6 Apr 21
Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat
4:59pm
8-K
EX-99.1
6hcf5nk8s0lfq7s
1 Mar 21
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
4:06pm
8-K
9m6 ckfrxyl
1 Dec 20
Departure of Directors or Certain Officers
8:05am
8-K
EX-99.1
ykwpwk93
5 Nov 20
FibroGen Reports THIRD Quarter 2020 Financial Results
4:05pm
8-K
EX-99.1
ihwbr32
6 Aug 20
FibroGen Announces New Appointments to its Board of Directors
4:06pm
8-K
EX-99.1
hq7kxegalol l93ve
2 Mar 20
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
4:06pm
8-K
EX-99.1
7ehasym
30 Jan 20
Astellas Submits Supplemental New Drug Application for Approval of
4:40pm
8-K
EX-99.2
6cd qhpa5zdc
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
EX-99.1
r7rd8le
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
EX-99.1
xc0kdy cckzyby8u
8 Nov 19
Regulation FD Disclosure
2:05pm
8-K
7vn0ilgsl990vr jz
8 Nov 19
Regulation FD Disclosure
2:05pm
8-K
u61nm
8 Nov 19
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
2:00pm